Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced the clinical advancement of three programs in development. The first program is a wholly-owned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE